Hepatotoxicity from antituberculous therapy in the elderly: A systematic review

Tuberculosis

Volumn 95, Issue 2, 2015, Pages 112-122

  Hosford, Jennifer D ^a,b   Von Fricken, Michael E ^b   Lauzardo, Michael ^a,b   Chang, Myron ^b   Dai, Yunfeng ^b   Lyon, Jennifer A ^b   Shuster, John ^b   Fennelly, Kevin P ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Aging; Antituberculous; Elderly; Hepatotoxicity; Latent tuberculosis; Systematic review; Therapy; Toxicity; Treatment; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

AGED; ANTIMICROBIAL THERAPY; CINAHL; CLINICAL EVALUATION; COCHRANE LIBRARY; COMORBIDITY; COMPARATIVE STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TREATMENT FAILURE; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; LATENT TUBERCULOSIS; LIVER FUNCTION; LIVER TOXICITY; MEDLINE; META ANALYSIS; MONOTHERAPY; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SCISEARCH; SYSTEMATIC REVIEW; AGE; DRUG-INDUCED LIVER INJURY; TUBERCULOSIS;

AGE FACTORS; AGED; ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; HUMANS; LATENT TUBERCULOSIS; RISK FACTORS; TUBERCULOSIS;

EID: 84924995718     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2014.10.006     Document Type: Review

References (52)

1. Centers for Disease Control and Prevention (CDC) Reported tuberculosis in the United States, 2011 2012 U.S. Department of Health and Human Services Atlanta, GA
2. H. Devarbhavi Antituberculous drug-induced liver injury: current perspective Trop Gastroenterol 32 3 2011 167 174
3. J.J. Saukkonen An official ATS statement: hepatotoxicity of antituberculosis therapy Am J Respir Crit Care Med 174 8 2006 935
4. H.M. Blumberg American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis Am J Respir Crit Care Med 167 4 2003 603 662
5. D.E. Griffith An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Am J Respir Crit Care Med 175 4 2007 367
6. A. Liberati The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med 6 7 2009 e1000100
7. P. Baghaei Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases Am J Ther 17 1 2010 17 22
8. A. Bartacek Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis Int J Tuberc Lung Dis 13 6 2009 760 766
9. R.B. Byrd Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients J Am Med Assoc 241 12 1979 1239 1241
10. J.Y. Chien Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment Int J Tuberc Lung Dis 14 5 2010 616 621
11. V.H. Chong Hepatobiliary tuberculosis: a review of presentations and outcomes South Med J 101 4 2008 356 361
12. N.K. Chou Various clinical presentations of tuberculosis in heart transplant recipients Transplant Proc 36 8 2004 2396 2398
13. P.P. Cook Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection Clin Infect Dis 43 3 2006 271 275
14. L.H. Ekochin Absence of transaminase elevation during concomitant methotrexate and isoniazid therapy J Rheumatol 36 9 2009 2127
15. C.A. Haley Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection Int J Tuberc Lung Dis 12 2 2008 160 167
16. A.W. Jahng Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period Transplantation 83 12 2007 1557 1562
17. A.H. Khan Anti-tubercular chemotherapy and drug induced hepatitis Healthmed 4 3 2010 536 544
18. Y.S. Kwon Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy Chest 131 3 2007 803 808
19. J.H. Lee Diagnostic and therapeutic problems of pulmonary tuberculosis in elderly patients J Korean Med Sci 20 5 2005 784 789
20. N. Lorent Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective Cohort study PLoS One 6 5 2011
21. D. Menzies Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial Ann Intern Med 149 10 2008 689 697
22. B.R. Meyers Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens Transplantation 69 1 2000 64 69
23. L.A. Nader Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor? Ann Hepatol 9 1 2010 70 74
24. C.M. Nolan, S.V. Goldberg, and S.E. Buskin Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic J Am Med Assoc 281 11 1999 1014 1018
25. L.P. Ormerod, and N. Horsfield Frequency and type of reactions to antituberculosis drugs: observations in routine treatment Tuber Lung Dis 77 1 1996 37 42
26. L.G. Possuelo Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil Eur J Clin Pharmacol 64 7 2008 673 681
27. S.J. Quantrill Side-effects of antituberculosis drug treatment in patients with chronic renal failure Eur Respir J 20 2 2002 440 443
28. T. Samandari 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial Lancet 377 9777 2011 1588 1598
29. T. Schaberg, K. Rebhan, and H. Lode Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis Eur Respir J 9 10 1996 2026 2030
30. L.K. Schluger Isoniazid hepatotoxicity after orthotopic liver transplantation Mt Sinai J Med 63 5-6 1996 364 369
31. N. Sen Tuberculosis in patients with end-stage renal disease undergoing dialysis in an endemic region of Turkey Transplant Proc 40 1 2008 81 84
32. P.H. Shang Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China PLoS One 6 7 2011
33. M. Sharifzadeh Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberclosis treatment Pharm Res 51 4 2005 353 358
34. M. Sistanizad Antituberculosis drug-induced hepatotoxicity in Iranian tuberculosis patients: role of isoniazid metabolic polymorphism Iran J Pharm Res 10 3 2011 633 639
35. B.M. Smith Adverse events associated with treatment of latent tuberculosis in the general population CMAJ 183 3 2011 E173 E179
36. T. Sotsuka Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients In Vivo 25 5 2011 803 812
37. J.E. Stout Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis Am J Respir Crit Care Med 167 6 2003 824 827
38. H.Y. Sun A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature J Formos Med Assoc 108 2 2009 102 111
39. S. Tariq Frequency of anti-tuberculous therapy-induced hepatotoxicity in patients and their outcome J Ayub Med Coll Abbottabad 21 4 2009 50 52
40. M.D. Teleman Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore Int J Tuberc Lung Dis 6 8 2002 699 705
41. P. van den Brande Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis Am J Respir Crit Care Med 152 5 Pt 1 1995 1705 1708
42. J.Y. Wang Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load J Infect 62 6 2011 448 455
43. H. Young A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts Clin Infect Dis 49 3 2009 424 427
44. Y. Zabana Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy Inflamm Bowel Dis 14 10 2008 1387 1391
45. R. Garibaldi Isoniazid-associated hepatitis. Report of an outbreak Am Rev Respir Dis 106 3 1972 357
46. CDC Treatment of tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America MMWR 52 2003 RR-11
47. R. Singla Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity Indian J Med Res 132 1 2010 81 86
48. H. Kunst, and K.S. Khan Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review [Review article] Int J Tuberc Lung Dis 14 11 2010 1374 1381
49. M.W. Borgdorff Transmission of Mycobacterium tuberculosis depending on the age and sex of source cases Am J Epidemiol 154 10 2001 934 943
50. H. Van Geuns, J. Meijer, and K. Styblo Results of contact examination in Rotterdam, 1967-1969 Bull Int Union Tuberc 50 1 1975 107
51. P. Thulin Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biiomarkers for drug-induced liver injury in two human cohorts Liver Int 34 3 2013 367 378
52. H. Zhang Identification of serum microRNA biomarkers for tuberculosis using RNA-seq PLoS One 9 2 2014 e88909